Analysts have been eager to weigh in on the Healthcare sector with new ratings on PDS Biotechnology (PDSB – Research Report) and Cartesian Therapeutics (RNAC – Research Report). PDS Biotechnology ...

Tuesday, Cartesian Therapeutics Inc (NASDAQ:RNAC) announced topline results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). Descartes-08, Cartesian’s lead ...

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Tuesday revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, lead cell therapy candidate, in participants with generalized ...

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Cartesian Therapeutics (RNAC). The reason why I want to go over this biotech next is because ...

FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today ...

Cartesian Therapeutics' stock has been volatile recently despite no significant news, driven by insider buying and mixed Phase 2b trial results for Descartes-08. The company's mRNA cell therapy ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company's share price sank ...

(MENAFN- GetNews) The Key Multiple Myeloma Companies in the market include - Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., CASI Pharmaceuticals, Sorrento ...

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards ...